Tesaro, Inc. (TSRO): Edward C English , VP of Finance & Administration of Tesaro, Inc. sold 7,000 shares on Jun 10, 2016. The Insider selling transaction was reported by the company on Jun 14, 2016 to the Securities and Exchange Commission. The shares were sold at $41.21 per share for a total value of $285,274.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Mar 18, 2016, Beth C Seidenberg (director) purchased 1,420,858 shares at $35.19 per share price.On Mar 18, 2016, Arnold L Oronsky (director) purchased 142,085 shares at $35.19 per share price.Also, On Mar 14, 2016, Edward C English (VP of Finance & Administration) sold 7,000 shares at $43.54 per share price.On Sep 9, 2015, James O Armitage (director) purchased 500 shares at $54.63 per share price.
Shares of TESARO Inc (TSRO) ended Friday, Jun 10, 2016 session in red amid volatile trading. The shares closed down -1.48 points or -3.54% at $40.34 with 7,99,628 shares getting traded. Post opening the session at $41.03, the shares hit an intraday low of $40.02 and an intraday high of $41.95 and the price vacillated in this range throughout the day. The company has a market cap of $1,849 M and the number of outstanding shares has been calculated to be 4,58,45,028 shares. The 52-week high of TESARO Inc is $66.95 and the 52-week low is $29.51.
Company has been under the radar of several Street Analysts.TESARO Inc is Initiated by Credit Suisse to Outperform. The Rating was issued on May 13, 2016.TESARO Inc is Initiated by FBR Capital to Outperform and the brokerage firm has set the Price Target at $65. The Rating was issued on Apr 13, 2016.
TESARO Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates rolapitant niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1 or NK-1 receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib formerly known as MK-4827 is an orally active and potent poly (ADP-ribose) polymerase and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio Inc. for the discovery and development of antibodies for several specified immuno-oncology targets.